Genda-Bio’s next-gen platform couples AI design, high-throughput primary-cell screening, and peptide-based, non-viral delivery for nucleic acids.
Nucleic acid delivery remains the critical bottleneck in gene function studies and therapeutic applications. Genda-Bio leverages proprietary peptide engineering to harness the innate biocompatibility and phase separation properties of natural peptides, pioneering the GentleFectTM platform. Inspired by native cellular mechanisms, it surpasses liposomal and viral vectors, enabling high-efficiency, low-toxicity delivery of exogenous nucleic acids and offering a new solution for transfecting primary and hard-to-transfect cells.
l Basic Research: CRISPR editing, gene modulation, and pathway studies in all cell types; especially in primary-cell validation and hard-to-transfect tumor models—trusted by 1,500+ teams.
l Cell therapy: Non-viral nucleic-acid delivery for Stem cells and T cells with minimal toxicity, sustaining cell viability; adopted in multiple pre-clinical programs.